- Adults
- Elderly
- Fragile population
- Immunocompromised host
- Hospital wide
- Emergency department
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Remdesivir
Population: Elderly
Individuals aged 65 years and above
- Adults
- Elderly
- Fragile population
- Immunocompromised host
- Hospital wide
- Outpatient clinic
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab
- Tixagevimab/Cilgavimab
- Casirivimab/Imdevimab
- Adults
- Elderly
- Fragile population
- Paediatric
- Emergency department
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab
- Adults
- General population
- Elderly
- Hospital wide
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Statins
- Adults
- General population
- Elderly
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Adults
- General population
- Elderly
- Hospital wide
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Adults
- General population
- Elderly
- Hospital wide
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Adults
- Elderly
- Fragile population
- People at high risk of STIs
- Men who have sex with men
- People living with HIV
- Hospital wide
- Outpatient clinic
- Infectious diseases unit
- Monkeypox virus
- Mpox
- Adults
- General population
- Elderly
- Paediatric
- Hospital wide
- Outpatient clinic
- Community
- Non-hospital health centre
- SARS-CoV-2
- Acute COVID-19
- Adults
- General population
- Elderly
- Paediatric
- Monkeypox virus
- Mpox
- Pharmacological intervention
- Antivirals
- Tecovirimat
- Adults
- General population
- Elderly
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Neurostimulation
- Adults
- Elderly
- Fragile population
- Hospital wide
- Intensive care unit
- SARS-CoV-2
- Post-COVID-19